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Granulocyte colony-stimulating factor (G-CSF) and 
granulocyte-macrophage colony-stimulating factor 
(GM-CSF) are glycoproteins which have substantial 
effects on the proliferation and differentiation of 
neutrophils, the latter also influencing macrophages. 
They are therapeutically used in cases where increasing 
the neutrophil count is essential, as in neutropenic, 
immunocompromised or cancer patients. However, an 
additional effect of CSF on the activation of mature 
neutrophils has been demonstrated in experimental 
models [I .2]. The predominant function of neutrophils 
in cellular defense suggests a key position of CSF, 
which is underlined by its increase during infection. 
This aroused interest in using CSF for specifically 
improving the immune response during infections 
in non-neutropenic patients without malignancies. 
Unlike the regular indications, where CSF acts 
prophylactically, this indication is focused on the 
immediate cell-activating therapeutic effect after onset 
of infection which might act additionally or even 
in synergy with antibiotics. G-CSF and GM-CSF 
have therefore been investigated in numerous studies 
examining the immune modulating effect and possible 
synergy with antibiotics as well as side effects, in 
vitro, in animal infection models, and with activated 
polymorphonuclear leukocytes (PMNLs) from CSF- 
treated patients or volunteers. There are also some 
reports on the therapeutic use of CSF in patients with 
severe infections. 
The in vitro synergistic effect resulting from 
combining G-CSF and antibiotics was demonstrated by 
lulling of Escherichia coli in the presence of G-CSF and 
ceftazidime or ofloxacin [3,4] . Animal models showed 
the positive eEect of G-CSF on different types of 
infection. Of special interest are those with an under- 
lying immunologic dysfunction other than neutropenia, 
such as infection after trauma, burn, intoxication, 
splenectomy or neonatal sepsis. Neonatal PMNLs are 
deficient in chemotaxis and show a reduced oxidative 
response in times of stress. As neonatal sepsis is usually 
characterized by neutropenia, efficacy of G-CSF in 
therapeutic treatment may be due to both the granulo- 
poietic and the stimulating effects. In a model of 
experimental group B streptococcus (GBS) sepsis 
in newborn rats, G-CSF and ampicillin (150 mg/kg 
per day) or gentamicin (6.5 mg/kg per day) had a 
significant synergistic effect on survival. Treatment 
with G-CSF alone yielded a 9% survival rate, single 
antibiotic treatment 28% and combined treatment 91%, 
versus 4% in the control group (plO.OO1). G-CSF 
pulse prophylaxis (5 pg/kg) 6 h before GBS inoculation 
combined with antibiotics increased survival to 70% 
versus 10% after single antibiotic treatment (p10.01) 
[5]. In a follow-up, 7-day prophylaxis versus pulse 
treatment 6 or 18 h after GBS inoculation was 
compared. Prophylaxis (5 pg/kg per day) significantly 
increased peripheral neutrophilia and the bone marrow 
neutrophil storage pool (~10.001) .  Its synergy with 
antibiotic treatment was shown by 48-h/72-h survival 
rates of 100% each with combined treatment, and 
90%/50% with antibiotics alone, 40%/0% with G-CSF 
alone, versus 0% each in the controls. Pulse treatment, 
however, yielded neither synergy with antibiotics 
nor improved survival, and did not prevent neutropenia 
Trauma and burn patients with severe infections 
might possibly benefit from G-CSF treatment. In a 
mouse hemorrhage and trauma model, administration 
of G-CSF starting 2 or 4 days prior to and continuing 
for 7 days after induction of a Pseudomonas aeruginosa 
pneumonia increased survival to 38% versus 8% in 
controls. Significance could be achieved with a dose 
of 100 pg/kg per day, but not with 50 pg/kg per day 
[7]. Burned mice with Pseudomonas aeruginosa wound 
infection showed a significant improvement after 
gentamicin (once 6 mg/kg IP immediately after burn) 
and G-CSF treatment (200 ng/day, 7 days) alone or 
in combination, compared to controls (p<0.001 for all 
groups). Combined treatment yielded higher survival 
rates than single gentamicin (p'0.007) or single G- 
CSF administration ( ~ ~ 0 . 0 5 4 )  [8]. 
In the immunocompetent host, management of 
systemic infections may also be difficult because often 
only a few effective antibiotics are available, which 
makes a single or a synergistic CSF treatment an 
important option. G-CSF treatment provided signi- 
ficant protection in a murine model of lethal fecal 
peritonitis. However, this effect was only obtained with 
2 days' prophylaxis (100 pg/kg per day), and not with 
an immediate pretreatment 191. In contrast to this, in a 
rat model of cecal ligation and puncture (CLP) a 
significant decrease in mortality was noted when G- 
CSF (15pg IP) was administered once after onset of 
sepsis (y<O.001) [lo]. This was verified in a later 
study of a similar model, where G-CSF treatment at  
20 pg/kg per day starting 4 h after sepsis induction 
[61. 
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sigificantly reduced the mortality rate from 96% to 
42‘% (piO.05). This protection could not be signifi- 
cantly improved, either by increasing the dose or by an 
additional prophylactic application [ 1 11. 
Combination of G-CSF (different doses) and 
gentaniicin (1 x 15 nig/kg) was investigated in a Inurine 
CLI’ model. Single G-CSF treatment significantly 
increased survival, with dose- arid time-dependent 
efficacy. Combined therapy yielded significantly 
improved survival compared to lion-treated animals 
(p=0.001) and to single G-CSF treatment (p=0.0475) 
but not to single gentamkin treatment [ 121. Essdierichia 
co/i peritonitis in rats had a significantly increased 
survival rate (78% versus 38%) when animals were 
treated with ceftriaxone (14.3 nig/kg) combined with 
a ‘-day G-CSF pretreatment (1 00 pg/kg per day) [ 131. 
In experimental disseminated candidosis in mice, 
G-CSF had no direct benefit, but conibined with 
fluconazole could extend the survival beyond that for 
fluconazole alone [14]. Conibined therapy with 
penicillin G and G-CSF gave a higher survival rate than 
penicillin G done i n  a rabbit Pnsteuvdln m4liocida 
pneunionia and sepsis model. Iniprovenient was 
significant only i n  the group where sepsis was 
complicated by leukopenia. However, this effect mainly 
occurred prior to increase in neutrophil count, 
suggesting functional activation rather than neutrophil 
number or modulation of cytokine release being the 
cause [151. Administration of G-CSF in catheter- 
related endocarditis seems to be less efficacious, as 
shown in a rabbit model of Staphylococcus nureus 
endocarditis, where G-CSF (25 pg/kg per day for 3 
days) alone or conibined with ceftriaxone (501ng/kg 
per day for 3 days) did not lead to an improved outcome 
[ 161. I n  a rabbit ~xV!doJnor?ns nrvuginosa endocarditis 
model, G-CSF (100 &kg per day) given 3 dayc after 
bacterial challenge iieither had an antibacterial effect 
nor increased the efficacy of ciprofloxacin (80 mg/kg 
per day). Only treatment starting 30 niin prior to 
challenge yielded a significant but transient anti- 
iiiicrobial effect [ 171. 
Up to now, there have been few reports published 
on treatment of infections in non-neutropenic patients 
with CSF. Liles et a1 examined the antifungal activity of 
PMNLs from three healthy normal human volunteers 
before and after G-CSF administration. The killing rate 
did not  change rignificantly for Cntrdida nlbicans. but 
increased four-fold for As~e~~illLlsfrrr,iieatus and 15-fold 
for Rhizopus avvliizrrs (p<O.05). Absolute iieutrophil 
count increased about six-fold after five G-CSF doses 
(300 iiig/day SC). Enhancement of respiratory burst 
xtivity in response to extracts of hyphae and conidia 
\vCis generally slower in onset but sustained in 
comparison to the rapid but brief respiratory burst after 
in vitro G-CSF pretreatment of control PMNLs 111. In 
a prospective, controlled, randomized study, Gillan et a1 
examined 42 newborn infants with presumed bacterial 
sepsis within the first 3 days of life. G-CSF was 
administered at 1, 5 and 10 pg/kg per day or 5 and 
10 pg/kg per 12 h. Doses of 5 or 10 pg/kg induced 
a significant increase in absolute neutrophil count 
(ANC), with a maximurn of 397% or 621% after 72 h, 
and a dose-dependent two- to threefold increase in 
the neutrophil storage pool (NSP) was observed. A 
significant increase in neutrophil C3bi expression 
suggested a possible enhancernent of PMNL adherence 
or aggregation leading to improved function and 
increased toxicity [18]. Nakazawa et a1 reported on a 2- 
month-old boy with a large niultilocular l-’asteuve/la 
mmltoc-ida brain abscess. Intravenous injection of high 
doses of antibiotics and antibiotic irrigation of the 
abscess cavity could not prevent exacerbation by absent 
ANC increase. After additional rhC-CSF application 
(125 pg SC), neutrophil count mas raised, and ini- 
proved cheniotaxis and superoxide anion production of 
the neutrophils was observed, resulting in prompt 
clinical and laboratory improvements [19]. Mueller- 
Werdan et a1 described the treatment of a patient 
with septic granuloniatosis developing a cevere sepsis 
with initial heniodynaniic instability. As the infection 
seemed to be resistant to every antibiotic therapy 
tried, interferon was contraindicated for intolerance, 
and leukocyte transfusions were not available, G-CSF 
treatnient (300 pg/day) was started, resulting in d 
dramatic clinical amelioration with teinperature 
decrease and reniiscion of disseminated intravascular 
coagulation (DIC). Antibiotics weie stopped a t  the fifih 
day of G-CSF treatment. Three days later tlie patient 
was  afebrile and showed no more symptoms of 
infection. Leukocyte analysis revealed an increased 
ANC but unchanged oxidative function [20]. Nelson 
et a1 investigated the use of G-CSF in the treatment of 
hospitalized patients with community-acquired pneu- 
monia in a large multicenter double-blind trial. They 
enrolled 380 patients treated with G-CSF (300 &day 
SC for 10 days) and 376 placebo-treated controls. 
G C S F  elevated ANCs three-fold but did not  lead 
to significant differences in mortality rate, time to 
resolution of morbidity and length of hospital stay. 
However, significant differences were rioted on the 
intention-to-treat analysis. The comparison between 
treated versus control patients revealed adult respiratory 
distress syndrome in 4 versus 14 patients (p=0.017), 
1)IC in 0 versus 7 patients (p=0.007) and enipyenici 
in 1 versus 7 patients (p=0.037). Median time to 
resolution in the chest radiograph was 29 days in 
treated patients versus 42 days in controls (p=O.O01). 
Complete resolution in tlie chest radiograph by day 28 
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was found in 58% of treated versus 42% of control 
patients (p=0.005) [21]. 
In contrast to G-CSF, experimental models 
investigating the effect of GM-CSF did not reveal 
consistent results. In a CLP model, rats received a single 
dose of 20 pg GM-CSF 3 h after onset of infection. 
There was no improvement of survival rates after 48 h 
and even earlier deaths than in the control group were 
observed. Neutrophil counts in the peritoneal lavage 
fluid were lower in the GM-CSF-treated group, 
indicating inhibition of neutrophil migration [22]. In 
the above mentioned model of fecal peritonitis, G-CSF 
treatment yielded a significant protection whereas GM- 
CSF (50/100 pg/kg immediate or 2 days’ prophylaxis) 
failed to protect animals, the mortality being 100%. 
It could not raise leukocyte counts and significantly 
increased levels of circulating TNF-a [9]. In a murine 
model of septic shock, G-CSF (50 g/kg) protected 
galactosamine-sensitized mice from lipopolysaccharide 
(LPS)-induced hepatitis and decreased LPS-induced 
serum T N F  activity. In contrast, pretreatment with 
GM-CSF (50 pg/kg) resulted in significantly higher 
TNF activity and increased mortality [23]. 
However, in newborn rats with group B strepto- 
coccal sepsis combined, GM-CSF (1 x 0.05 pg/kg) 
and penicillin (3 x 100 mg/kg) treatment significantly 
decreased the mortality rate in comparison to penicillin 
alone (39% versus 76%) [24]. There are also some 
studies ofwound and burn infections that have reported 
a positive effect of GM-CSE In a model of Pseudomonas 
aeruginosa-infected burn injury, mice treated with GM- 
CSF (20 ng/day) had a significantly improved survival 
rate [25]. A significant increase in wound healing after 
GM-CSF treatment was found in a rat model of 
acute and chronic wound healing. Wound bacterial 
counts decreased in the treated group, with significance 
only at day 7 [26]. In a murine model of Klebsiella 
pneumoniae suture infection, the combination of GM- 
CSF, TNF-a, the immune adjuvant muramyl dipeptide 
and cefoxitin or ampicillinsulbactam was investigated. 
After GM-CSF treatment, the survival rate was worse 
(2%) than in control animals (18%). Combination of 
immunomodulators yielded modest increases (50%). 
Combination of all immunostimulating substances 
with one antibiotic yielded significant increases in 
survival rate (84% cefoxitin, 90% ampicillin-sulbactam) 
[27]. 
Positive effects of GM-CSF treatment were shown 
in a report of a 42-year-old woman with underlying 
insulin dependent diabetes mellitus and chronic 
mucocutaneous candidosis resistant to conventional 
antifungals. Neutrophils showed reduced chemotaxis to 
bacterial factor and zyniosyme. Treatment with GM- 
CSF 7 pg/kg per day for 2 weeks and on alternate days 
thereafter cleared all fungal lesions completely within 
1 week and yielded a substantial improvement in 
neutrophil chemotaxis, an increased monocyte count 
and increased interleukin-I secretion [28]. 
We conclude from this literature review that 
G-CSF and to a lesser extent GM-CSF seem to 
be efficacious for prophylaxis and as supplementary 
treatment of various infectious diseases. However, 
further clinical studies must be done in order to 
precisely define the indications and also to reveal 
potential side effects. 
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